On August 3, SKB BIO declined 3.35% in regular trading, trading at HK$470.8/share, with turnover of HK$50.87 million. The stock continues to face selling pressure as commercial bribery allegations surrounding its core ADC product sacituzumab tirumotecan (brand name: Jiatailai) remain unresolved.

A widely circulated whistleblower letter alleges that the company engaged in cash kickbacks of RMB 900-2,000 per dose of the drug priced at RMB 9,399, channeled funds exceeding RMB 8 million to clinical department heads at top-tier hospitals including Beijing 301 Hospital and Peking Union Medical College Hospital via sham academic conferences through charitable foundations, and gifted luxury items to physicians. SKB BIO has denied the allegations and stated it would pursue legal action against the whistleblower.

Compounding market concerns, China's stringent new Medical Representative Management Measures officially took effect on August 1, explicitly prohibiting nine categories of conduct including kickbacks and prescription tracking — provisions that closely mirror the allegations in the whistleblower letter. The timing has heightened investor scrutiny over the company's commercial compliance framework for its product that accounted for 97.6% of sales revenue.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)